Based on results from three independently reported meta-analyses of randomized controlled trials that compared low-intensity and high-intensity programs of colorectal cancer surveillance, and on recent analyses of data from major clinical trials in colon and rectal cancer, the Panel recommends annual computed tomography (CT) of the chest and abdomen for 3 years after primary therapy for patients who are at higher risk of recurrence and who could be candidates for curative-intent surgery; pelvic CT scan for rectal cancer surveillance, especially for patients with several poor prognostic factors, including those who have not been treated with radiation; colonoscopy at 3 years after operative treatment, and, if results are normal, every 5 years thereafter; flexible proctosigmoidoscopy [corrected] every 6 months for 5 years for rectal cancer patients who have not been treated with pelvic radiation; history and physical examination every 3 to 6 months for the first 3 years, every 6 months during years 4 and 5, and subsequently at the discretion of the physician; and carcinoembryonic antigen every 3 months postoperatively for at least 3 years after diagnosis, if the patient is a candidate for surgery or systemic therapy. Chest x-rays, CBCs, and liver function tests are not recommended, and molecular or cellular markers should not influence the surveillance strategy based on available evidence.
The amyloid- (A) peptide, which likely plays a key role in Alzheimer disease, is derived from the amyloid- precursor protein (APP) through consecutive proteolytic cleavages by -site APP-cleaving enzyme and ␥-secretase. Unexpectedly ␥-secretase inhibitors can increase the secretion of A peptides under some circumstances. This "A rise" phenomenon, the same inhibitor causing an increase in A at low concentrations but inhibition at higher concentrations, has been widely observed. Here we show that the A rise depends on the -secretase-derived C-terminal fragment of APP (CTF) or C99 levels with low levels causing rises. In contrast, the N-terminally truncated form of A, known as "p3," formed by ␣-secretase cleavage, did not exhibit a rise. In addition to the A rise, low CTF or C99 expression decreased ␥-secretase inhibitor potency. This "potency shift" may be explained by the relatively high enzyme to substrate ratio under conditions of low substrate because increased concentrations of inhibitor would be necessary to affect substrate turnover. Consistent with this hypothesis, ␥-secretase inhibitor radioligand occupancy studies showed that a high level of occupancy was correlated with inhibition of A under conditions of low substrate expression. The A rise was also observed in rat brain after dosing with the ␥-secretase inhibitor BMS-299897. The A rise and potency shift are therefore relevant factors in the development of ␥-secretase inhibitors and can be evaluated using appropriate choices of animal and cell culture models. Hypothetical mechanisms for the A rise, including the "incomplete processing" and endocytic models, are discussed.Evidence suggests that the amyloid- (A) 9 peptide plays a key role in Alzheimer disease. A is generated by proteolytic processing of the amyloid- precursor protein (APP) through consecutive cleavages by the -site APP-cleaving enzyme (BACE) and ␥-secretase. APP is cleaved by BACE to form a -secretase-derived C-terminal fragment of APP (CTF), which undergoes further cleavage by ␥-secretase to form A. In addition, APP is cleaved by ␣-secretase to form ␣CTF, which undergoes ␥-secretase cleavage to produce an N-terminally truncated form of A known as "p3." Using the conventional amino acid numbering of A, BACE cleavage leads to A peptides with N-terminal ends at positions 1 and 11, whereas ␣-secretase leads to p3 peptides with an N-terminal end at position 17. Cleavage of CTF and ␣CTF by ␥-secretase produces a mixture of different C termini in the resulting A and p3 peptides. For example, the predominant ␥-secretase cleavage of CTFs at position 40 produces A-(1-40) and A-(11-40), whereas other ␥-secretase cleavage sites produce a range of less abundant A peptides, such as the disease-associated A-(1-42) (1, 2).
American Society of Clinical Oncology.
RNA encoding the rat serotonin 5-HT
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.